BLK (AAH07371, 1 a.a. ~ 90 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. MGLVSSKKPDKEKPIKEKDKGQWSPLKVSAQDKDAPPLPPLVVFNHLTPPPPDEHLDEDKHFVVALYDYTAMNDRDLQMLKGEKLQVLKG
Localization
Nuclear
Specificity
BLK - B lymphoid tyrosine kinase
Isotype
IgG1 Kappa
Clonality
Monoclonal
Host
Mouse
Gene
BLK
Purity
IgG purified
Innovator's Reward
Test in a species/application not listed above to receive a full credit towards a future purchase.
Please note that this antibody is reactive to Mouse and derived from the same host, Mouse. Additional Mouse on Mouse blocking steps may be required for IHC and ICC experiments. Please contact Technical Support for more information.
Packaging, Storage & Formulations
Storage
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Buffer
In 1x PBS, pH 7.4
Preservative
No Preservative
Purity
IgG purified
Notes
Quality control test: Antibody Reactive Against Recombinant Protein.
This product is produced by and distributed for Abnova, a company based in Taiwan.
Alternate Names for Blk Antibody (7A12)
B lymphocyte kinase
B lymphoid tyrosine kinase
BLK nonreceptor tyrosine kinase
Blk
EC 2.7.10.2
MGC10442
MODY11
p55-Blk
tyrosine-protein kinase Blk
Background
The gene encoding BLK is a member of the SRC family of protooncogenes and shows preferential expression in B-lymphoid cells. It is thought to function in a signal transductory pathway specific to this lineage.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
We tested the monoclonal anti-BLK antibody, clone 7A12, in Western Blot for cross-reactivity to 3 other SRC family kinases (Lck, Lyn and Fyn) to determine if 7A12 cross-reacts with Lck in the same manner that the anti-BLK clones 9D10B7H6 and 9D10D1 do. 7A12 gave a positive band for rBLK (approximately 84kDa as expected), but not for rLCK, rLYN or rFYN. 7A12 also gave a positive band for Ramos, Jurkat, human thymus, CD4+ and CD8+ T cells (approximately 55kDa as expected).
Detection Method: Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, Nebraska)
Comments
Comments
We tested the monoclonal anti-BLK antibody, clone 7A12, in Western Blot for cross-reactivity to 3 other SRC family kinases (Lck, Lyn and Fyn) to determine if 7A12 cross-reacts with Lck in the same manner that the anti-BLK clones 9D10B7H6 and 9D10D1 do. 7A12 gave a positive band for rBLK (approximately 84kDa as expected), but not for rLCK, rLYN or rFYN. 7A12 also gave a positive band for Ramos, Jurkat, human thymus, CD4+ and CD8+ T cells (approximately 55kDa as expected).
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
Bioinformatics Tool for Blk Antibody (H00000640-M02)
Discover related pathways, diseases and genes to Blk Antibody (H00000640-M02). Need help?
Read the Bioinformatics Tool Guide for instructions on using this tool.
Diseases for Blk Antibody (H00000640-M02)
Discover more about diseases related to Blk Antibody (H00000640-M02).
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.